Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01122329 · ClinicalTrials.gov registry record · Phase 4
A Positron Emission Tomography (PET) Study Evaluating Brain Metabolism of a Medical Food in Alzheimer's Disease
A Phase 4 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 4
- Development phase
- 17
- Enrollment target
NCT01122329 is a Phase 4 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 17 participants.
The verdict
NCT01122329, a Phase 4 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 17 participants
- Enrollment target
Study Summary
This study will examine the brain metabolic effects of AC-1202 (Axona®), a medical food for Alzheimer's disease. Subjects who meet entry criteria will undergo H215O positron emission tomography prior to and 90 minutes after consumption of Axona® at baseline and then again after 45 days of treatment. Cognitive testing will also be conducted at baseline and day 45.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT caprylidene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2010-10 |
| Est. Completion | 2015-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01122329
The ClinicalTrials.gov registry entry for NCT01122329 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01122329 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01122329 about?
NCT01122329 is a clinical study titled "A Positron Emission Tomography (PET) Study Evaluating Brain Metabolism of a Medical Food in Alzheimer's Disease". This study will examine the brain metabolic effects of AC-1202 (Axona®), a medical food for Alzheimer's disease. Subjects who meet entry criteria will undergo H215O positron emission tomography prior to and 90 minutes after consumption of Axona® at baseline and then again after 45 days of treatment....
What is the current status of trial NCT01122329?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 17 participants. The study started on 2010-10. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01122329?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), caprylidene (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01122329?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.